EXACT Sciences Corporation  

(Public, NASDAQ:EXAS)   Watch this stock  
Find more results for EXAS
27.31
+0.76 (2.86%)
After Hours: 27.65 +0.34 (1.24%)
May 27, 7:43PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 26.29 - 27.34
52 week 13.02 - 29.97
Open 26.72
Vol / Avg. 958,579.00/1.62M
Mkt cap 2.39B
P/E     -
Div/yield     -
EPS -1.41
Shares 88.91M
Beta 1.23
Inst. own 99%
Jul 23, 2015
Exact Sciences Corp Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
Jul 20, 2015
Q2 2015 Exact Sciences Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 11, 2015
Exact Sciences Corp at Goldman Sachs Healthcare Conference - 12:20PM EDT - Add to calendar
Jun 10, 2015
Exact Sciences Corp at William Blair Annual Growth Stock Conference - 11:40AM EDT - Add to calendar
Jun 4, 2015
Exact Sciences Corp at Jefferies Global Healthcare Conference - 9:00AM EDT - Add to calendar
May 19, 2015
Exact Sciences Corp at UBS Global Healthcare Conference
May 12, 2015
Exact Sciences Corp at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Exact Sciences Corp at Robert W. Baird & Co. Inc's Growth Stock Conference
May 4, 2015
Q1 2015 Exact Sciences Corp Earnings Call
May 4, 2015
Q1 2015 Exact Sciences Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -839.22% -5564.40%
Operating margin -844.16% -5591.71%
EBITD margin - -5385.37%
Return on average assets -48.54% -43.55%
Return on average equity -52.49% -47.16%
Employees 236 -
CDP Score - -

Address

441 Charmany Dr
MADISON, WI 53719-1234
United States - Map
+1-608-2845700 (Phone)
+1-608-2845701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed an accurate, non-invasive, screening test for the early detection of colorectal pre-cancer and cancer. The Company’s Cologuard test is a non-invasive, stool-based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test (FIT). Its Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer.

Officers and directors

Kevin T. Conroy Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
William J. Megan Principal Financial Officer, Senior Vice President - Finance
Age: 58
Bio & Compensation  - Reuters
Maneesh K. Arora Chief Operating Officer, Senior Vice President
Age: 46
Bio & Compensation  - Reuters
Graham P. Lidgard Ph.D. Senior Vice President, Chief Scientific Officer
Age: 66
Bio & Compensation  - Reuters
David A. Thompson Lead Independent Director
Age: 73
Bio & Compensation  - Reuters
Thomas D. Carey Independent Director
Age: 53
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel J. Levangie Independent Director
Age: 64
Bio & Compensation  - Reuters
Katherine S. Napier Independent Director
Age: 60
Bio & Compensation  - Reuters